VinsBio – Digital Stand

Founded in 1997, VINS Bioproducts Limited has established itself as a leading force in the global biopharmaceutical sector, with its headquarters in Hyderabad, India. Renowned for its expertise in the research, development, and manufacturing of equine-derived immunoglobulins and antisera, VINS has expanded from regional origins to become a trusted international brand. The company’s mission is rooted in scientific integrity and a commitment to addressing neglected public health issues, particularly in tropical and developing regions where its life-saving products are most needed.

VINS’ flagship facility in Telangana operates under stringent quality standards, complying with WHO-GMP, PIC/S, and national regulatory requirements. This state-of-the-art manufacturing site is supported by one of the world’s largest equine farms, spanning 150 acres, with over 2,000 horses. This unique setup ensures self-sufficiency, exceptional quality control in plasma sourcing, and adherence to the highest levels of biosecurity and ethical animal care.

The company serves as a preferred supplier of antisera and immunoglobulins, with registrations in more than 30 countries and supplying life-saving drugs to over 110 countries. Its products are trusted by public health agencies, hospitals, and humanitarian organizations throughout Asia, Africa, Latin America, the Middle East, and Eastern Europe. VINS’ reliability is further underscored by collaborations with global health leaders such as the WORLD HEALTH ORGANIZATION (WHO) and the PAN AMERICAN HEALTH ORGANIZATION (PAHO). It is also Recognized by the DEPARTMENT OF SCIENTIFIC AND INDUSTRIAL RESEARCH (DSIR), India. Through these partnerships, VINS has played a key role in emergency interventions, epidemic responses, and vaccination campaigns.

VINS Bioproducts offers a broad portfolio of lifesaving drugs, including polyvalent and monovalent snake antivenoms tailored to region-specific venomous species, as well as scorpion antivenom, rabies antiserum, and antitoxins for diphtheria, tetanus, and mixed gas gangrene. With an unwavering commitment to innovation, operational excellence, and stringent regulatory compliance, the company consistently delivers reliable solutions that safeguard public health.

With a legacy built on scientific excellence and compassionate outreach to underserved populations, VINS continues to expand its reach and impact. Its steadfast pursuit of quality, innovation, and responsible growth remains central to its reputation as an indispensable partner in healthcare, dedicated to improving lives and advancing global health security.

Sample products